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Dose-response relationship between lower
serum magnesium level and higher
prevalence of knee chondrocalcinosis
Chao Zeng1, Jie Wei2,7, Robert Terkeltaub3,4, Tuo Yang1, Hyon K. Choi5, Yi-lun Wang1, Dong-xing Xie1,
David J. Hunter6, Yuqing Zhang5, Hui Li1, Yang Cui8, Liang-jun Li1,9 and Guang-hua Lei1*
Abstract
Background: The aim was to assess serum magnesium levels in relation to prevalence of knee chondrocalcinosis in
two population-based Chinese studies.
Methods: Data included in this analysis consisted of two population-based cross-sectional studies, i.e., the Xiangya
Hospital Health Management Center Study and the Xiangya Osteoarthritis (XO) Study I. A bilateral knee anteroposterior
radiograph was obtained from each subject. Radiographic knee chondrocalcinosis was present if there was definite
linear cartilage calcification. Serum magnesium concentration was measured using the chemiluminescence method.
We examined the relation of serum magnesium levels to prevalence of knee chondrocalcinosis using generalized
estimating equations.
Results: The prevalence of knee chondrocalcinosis was 1.4% in the Xiangya Hospital Health Management Center Study
(n = 12,631). Compared with the lowest tertile, the age, sex and body mass index (BMI)-adjusted odds ratios (ORs) of
chondrocalcinosis were 0.59 (95% CI 0.40–0.87) and 0.49 (95% CI 0.33–0.72) in the second and the third tertiles of
serum magnesium, respectively (P for trend <0.001). The prevalence of knee chondrocalcinosis in the XO Study I
(n = 1316) was 4.1%. The age, sex and BMI-adjusted ORs of chondrocalcinosis were 0.67 (95% CI 0.34–1.30) in the
second and 0.45 (95% CI 0.21–0.94) in the third tertile of serum magnesium when compared with the lowest
tertile (P for trend = 0.030). Similar results were observed in men and women in both studies. Adjusting for additional
potential confounders did not change the results materially.
Conclusions: Subjects with lower levels of serum magnesium, even within the normal range, had higher prevalence of
knee chondrocalcinosis in a dose-response relationship manner, suggesting that magnesium may have a preventive or
therapeutic potential for knee chondrocalcinosis.
Keywords: Chondrocalcinosis, Magnesium, Knee
Background
Calcium pyrophosphate deposition (CPPD) in articular
fibrocartilage and hyaline cartilage, termed chondrocalci-
nosis, has been considered to be associated with both
aging and osteoarthritis [1]. CPPD, together with basic
calcium phosphate (BCP), are the two main components
of calcium-containing crystals in cartilage in osteoarth-
ritis [2, 3]. While most subjects with chondrocalcinosis
have no clinical symptoms (asymptomatic CPPD) [4],
CPPD may promote articular degeneration (osteoarth-
ritis with CPPD) and traffic of the crystals from articular
cartilage into the joint space; and thus can stimulate
acute episodic crystal arthritis and can also lead to
chronic inflammatory arthritis.
To date, only a few risk factors have been identified for
the occurrence of chondrocalcinosis. Studies have shown
that prevalence of chondrocalcinosis varied in different
ethnic groups. For example, prevalence of chondrocalci-
nosis was much lower in Beijing Osteoarthritis Study par-
ticipants (1.8% in men, 2.7% in women) than that in white
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subjects among the predominantly white participants in
the Framingham Study (6.2% in men, 7.7% in women) [5].
Several studies also found that knee chondrocalcinosis is
associated with low levels of serum magnesium [6–11].
For instance, patients with hypomagnesemia (e.g., poor
parenteral nutrition, short bowel syndrome, Gitelman syn-
drome or familial heredity) had a much higher prevalence
of chondrocalcinosis (up to 23.1%) [6–11]. However, these
findings were often based on subjects with extremely low
serum magnesium, and it remains unclear whether more
modest variations of magnesium levels observed in the
general population are associated with the prevalence of
chondrocalcinosis. Such potential associations and their
quantification would have an implication in public health
and clinical practices.
To fill in this knowledge gap, we used data collected
from two large population-based studies (i.e., Xiangya
Hospital Health Management Center Study and Xiangya
Osteoarthritis (XO) Study I) and examined the relation
of serum magnesium levels with the prevalence of knee
chondrocalcinosis and to determine the shape of the
dose-response relationship between serum magnesium
levels and the prevalence of knee chondrocalcinosis.
Methods
Study population
Xiangya Hospital Health Management Center Study
Subjects included in this study were residents living in
Hunan, China, who were undergoing routine health
examination at Xiangya Hospital, Central South Univer-
sity, China. The study design has been published else-
where [12–14]. In brief, routine health checkup included
anthropometric (e.g., height, weight, etc.), basic clinical
examination (e.g., blood pressure, heart rate, etc.), and bio-
chemical (e.g., blood routine examination, hepatic func-
tion, renal function, trace elements test, etc.) and imaging
tests (e.g., chest radiography, weight-bearing bilateral an-
teroposterior knee radiography, etc.). Subjects included in
the current analysis were those who: (1) had health
checkup between October 2013 and December 2015; (2)
were age ≥40 years; (3) underwent a serum magnesium
test; and (4) had bilateral weight-bearing anteroposterior
radiographs. All interviewers, clinical examiners and x-ray
technicians were trained by the principal investigators (CZ
and GL) before the study began.
Of 14,715 participants who underwent routine health
examination, 2081 (14.1%) were excluded from the ana-
lysis for the following reasons: (1) age <40 years old (n =
1408); (2) low quality of weight-bearing anteroposterior
knee radiographs (n = 63); (3) the Kellgren-Lawrence (K-
L) [15] grades of both knees were 4 (n = 8); and (4) re-
peated health examinations in the same person during
the study period (n = 604). Finally, 12,631 participants
were included in the analysis.
Xiangya Osteoarthritis Study I (XO Study I)
Subjects included in this study were a randomly selected
sample of residents, age ≥50 years, from eight rural
mountainous communities of Longshan County [16],
Hunan Province, for a study of osteoarthritis. All of the
villages in the selected communities were listed in a ran-
dom order. Beginning with the first village in the first
community, all residents age ≥50 years were invited to
participate in our study. The village-to-village recruit-
ment continued until the number of subjects in that
community met the predetermined quota according to
the Sixth National Census Data of Longshan County
(2010). Subjects were recruited at the site near their
home and were transported to the hospital for interview
and clinical examination between November 2015 and
January 2016. Trained health professional interviewers
administered a standardized questionnaire that focused
on sociodemographic factors, lifestyle habits, joint symp-
toms, joint functions, quality of life, dietary intake, medica-
tion use and other potential risk factors for osteoarthritis.
Clinical examination, laboratory testing and radiography
were also conducted at the time of interview. All inter-
viewers, clinical examiners and x-ray technicians were
trained under the supervision of the study principal investi-
gators (CZ and GL).
Of 1739 age-eligible (i.e., age ≥50 years) residents ran-
domly selected in Longshan County, 270 (15.5%) subjects
declined to participate the study. There was no significant
difference in sex and age distribution between subjects
who consented to participate and who declined (P = 0.42
and 0.47, respectively). Among 1469 participants in the
XO Study I, 153 were excluded from the analysis because
of: (1) history of lower limb surgery (n = 37); (2) history of
pelvic surgery (n = 1); (3) lower extremity disability due to
cerebrovascular diseases (n = 2) or spinal diseases (n = 2);
(4) rheumatoid arthritis (n = 61); (5) unavailability of knee
radiographs (n = 3); (6) low quality of weight-bearing an-
teroposterior radiographs of the knees (n = 1); (7) K-L
grades of 4 (n = 5) in both knees; and (8) unavailability of
a serum magnesium test (n = 41). Finally, 1316 partici-
pants were included in the analysis.
Blood biochemical analysis
All blood samples were drawn after a 12-hour overnight
fast and were stored at 4 °C until analysis. The serum
magnesium concentration was measured using the
chemiluminescence method by Beckman Coulter AU
5800 (Beckman Coulter Inc., Brea, CA, USA). The inter-
assay and intra-assay coefficients of variation were tested
by low concentrations (0.60 mmol/L of serum magne-
sium) and high concentrations (1.00 mmol/L of serum
magnesium) of standard human samples. The intra-
assay coefficients of variation were 1.86% (0.60 mmol/L)
and 1.65% (1.00 mmol/L) for serum magnesium, and the
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inter-assay coefficients of variation were 1.87% (0.60 mmol/
L) and 1.70% (1.00 mmol/L) for serum magnesium. Meas-
uring methods and reliability data of potential confounders
(e.g., serum parathyroid hormone, iron, ferritin, total iron
binding capacity, calcium, copper, zinc, phosphorus and
vitamin D) are shown in Additional file 1.
Assessment of radiographic knee chondrocalcinosis
All radiographs were assessed by two orthopedic surgeons
(TY and YLW) who were blinded to subjects’ clinical
symptoms and biochemical test results. Radiographic
chondrocalcinosis was defined as present when there was
evidence of definite linear cartilage calcification in the
knee [17]. Specifically, prior to starting the assessment,
these two orthopedists re-read 200 radiographs from the
Osteoarthritis Initiative (OAI) to calibrate their reading.
Formal readings of batches of randomly selected radio-
graphs did not start until the readers reached a high level
of agreement with previous readings from OAI (the spe-
cific cutoff of simple kappa for inter-rater reliability was
0.70). During the formal reading, one batch of knee radio-
graphs (100 radiographs) consisting of 10 previously read
radiographs selected at random and 90 unread radio-
graphs were mingled and read. For each batch, 90 unread
radiographs were used to test inter-rater reliability and 10
previously read radiographs were used to test intra-rater
reliability, respectively. Two readers both assessed all
radiographs and inconsistencies were resolved through
discussion. The kappa value for reliability readings of ra-
diographs from Xiangya Hospital Health Management
Center Study was 0.72 (95% CI 0.67 − 0.77) for inter-rater
reliability and 0.76 (95% CI 0.67–0.85) for intra-rater reli-
ability. The kappa value for reliability readings of radio-
graphs from XO Study I was 0.75 (95% CI 0.68–0.83) for
inter-rater reliability and 0.80 (95% CI 0.65–0.94) for
intra-rater reliability.
Statistical analysis
Continuous data were expressed as the mean ± standard
deviation, and categorical data were expressed as pro-
portion (percentage). The serum magnesium concentra-
tion was classified into three categories based on the
tertiles distribution in each study population (i.e., ≤ 0.86,
0.87–0.91 and ≥ 0.92 mmol/L in the Xiangya Hospital
Health Management Center Study and ≤ 0.89, 0.90–0.95
and ≥ 0.96 mmol/L in the XO Study I). We calculated
the sex-specific prevalence of chondrocalcinosis for each
category of serum magnesium. We examined the associ-
ation of serum magnesium categories and prevalence of
chondrocalcinosis using generalized estimating equa-
tions (GEE) [18], adjusting for the potential confounders
(knee specific analysis). Odds ratios (OR) and related
95% confidence intervals (95% CI) of chondrocalcinosis
among different categories of serum magnesium were
calculated using the PROC GENMOD procedure in SAS
with binomial distribution and logit links, and the lowest
tertile of serum magnesium was considered as the refer-
ence. We also calculated the OR and the related 95% CI
by using the category ≤0.70 mmol/L (dividing the lowest
category of serum magnesium into two categories:
≤0.70 mmol/L and 0.71–0.86 in the Xiangya Hospital
Health Management Center Study, and the category
≤0.70 mmol/L and 0.71–0.89 in the XO Study I) as the
reference group. Specifically, in the Xiangya Hospital
Health Management Center Study we first adjusted for
age (40–49, 50–59, 60–69, ≥70 years), body mass index
(BMI) (<25, ≥25 kg/m2) and sex (male, female). Then we
added each of the following covariates separately: serum
iron (tertiles), serum ferritin (tertiles), serum calcium,
serum zinc (tertiles), serum copper (tertiles), serum
phosphorus (tertiles), education (high school or above,
lower than high school) and occupation (manual labor,
non-manual labor) in the regression model adjusted for
age, sex and BMI. In the XO Study I, we first adjusted
for age (50–59, 60–69, ≥70 years), BMI (<25, ≥25 kg/m2)
and sex (male, female), and then added each of the fol-
lowing covariates separately in the regression models.
These covariates included knee injury, serum parathyroid
(tertiles), serum iron (tertiles), serum total iron binding
Table 1 Basic characteristics of the population in the Xiangya
Hospital Health Management Center Study (n = 12,631)
Tertiles of serum Mg (mmol/L)
1 (≤0.86) 2 (0.87–0.91) 3 (≥0.92)
Number 4633 3720 4278
Median Mg level (mmol/L) 0.83 0.89 0.95
Sex (female, %) 45.3 42.5 40.9
Age (years) 52.1 ± 8.1 52.4 ± 8.1 52.5 ± 7.9
40–49 (%) 43.5 41.1 39.5
50–59 (%) 37.5 39.5 40.4
60–69 (%) 15.2 15.9 17.2
≥70 (%) 3.8 3.5 2.9
BMI (kg/m2) 24.5 ± 3.4 24.4 ± 3.3 24.4 ± 3.2
<25 (%) 57.6 59.2 58.6
≥25 (%) 42.4 40.8 41.4
Serum iron (μmol/L) 18.1 ± 6.5 18.4 ± 6.3 18.9 ± 6.5
Serum ferritin (μg/L) 78.4 ± 67.3 78.3 ± 68.2 81.5 ± 62.8
Serum calcium (mmol/L) 2.4 ± 0.1 2.4 ± 0.1 2.4 ± 0.1
Serum zinc (μmol/L) 13.1 ± 2.5 13.5 ± 2.6 13.7 ± 3.1
Serum copper (μmol/L) 16.1 ± 3.6 16.2 ± 3.4 16.8 ± 3.8
Serum phosphorus (mmol/L) 1.2 ± 0.2 1.2 ± 0.2 1.2 ± 0.2
Education (high school or
above, %)
42.3 49.8 49.0
Occupation (manual labor, %) 20.1 17.2 17.5
Mg magnesium, BMI body mass index
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capacity (tertiles), serum unsaturated iron binding capacity
(tertiles), serum calcium (tertiles), serum 25(OH)D (ter-
tiles), serum zinc (tertiles), serum copper (tertiles), serum
phosphorus (tertiles), education (educated, non-educated)
and occupation (farmer, non-farmer).
In addition, we performed sex-specific analysis to
examine the levels of serum magnesium and prevalence
of chondrocalcinosis. The dose-response relationship be-
tween levels of serum magnesium and the prevalence of
knee chondrocalcinosis was evaluated by restricted cubic
splines regression with two knots defined by the tertile
distribution of serum magnesium [19, 20]. We also used
the value 0.7 mmol/L as an additional knot, to evaluate
the dose-response association between serum magne-
sium and the prevalence of knee chondrocalcinosis.
Results
Xiangya Hospital Health Management Center Study
Of the remaining 12631 participants from the initially
included 14,715 participants, 43.0% (n = 5428) were
Fig. 1 Dose-response relationship between serum magnesium (Mg) level and the odds ratio (OR) for knee chondrocalcinosis (CC) in the Xiangya
Hospital Health Management Center Study. CI, confidence interval
Fig. 2 Association between serum magnesium (Mg) and predicted prevalence of chondrocalcinosis (CC) analyzed by spline regression in the
Xiangya Hospital Health Management Center Study
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Table 2 Association between serum Mg and knee chondrocalcinosis in the Xiangya Hospital Health Management Center Study (n =
12,631)
Tertiles of serum Mg (mmol/L) P for
trend1 (≤0.86) 2 (0.87–0.91) 3 (≥0.92)
Total
N for knee* 9263 7438 8497 -
Knee chondrocalcinosis (%) 1.3 0.8 0.6 -
Model 1 (95% CI) 1.00 (reference) 0.59 (0.40, 0.87) 0.49 (0.33, 0.72) <0.001
Model 2 (95% CI) 1.00 (reference) 0.59 (0.39, 0.89) 0.53 (0.36, 0.78) 0.001
Model 3 (95% CI) 1.00 (reference) 0.69 (0.36, 1.32) 0.38 (0.20, 0.71) 0.002
Model 4 (95% CI) 1.00 (reference) 0.60 (0.41, 0.89) 0.48 (0.33, 0.71) <0.001
Model 5 (95% CI) 1.00 (reference) 0.58 (0.39, 0.88) 0.52 (0.35, 0.78) 0.001
Model 6 (95% CI) 1.00 (reference) 0.57 (0.38, 0.86) 0.49 (0.33, 0.73) <0.001
Model 7 (95% CI) 1.00 (reference) 0.60 (0.41, 0.89) 0.48 (0.33, 0.72) <0.001
Model 8 (95% CI) 1.00 (reference) 0.83 (0.43, 1.58) 0.46 (0.23, 0.90) 0.021
Male
N for knee* 5065 4279 5058 -
Knee chondrocalcinosis (%) 1.4 0.7 0.5 -
Model 1 (95% CI) 1.00 (reference) 0.56 (0.33, 0.95) 0.43 (0.25, 0.74) 0.002
Model 2 (95% CI) 1.00 (reference) 0.54 (0.31, 0.96) 0.45 (0.26, 0.78) 0.003
Model 3 (95% CI) 1.00 (reference) 0.65 (0.27, 1.56) 0.37 (0.16, 0.84) 0.017
Model 4 (95% CI) 1.00 (reference) 0.57 (0.34, 0.98) 0.42 (0.24, 0.73) 0.002
Model 5 (95% CI) 1.00 (reference) 0.54 (0.30, 0.94) 0.45 (0.26, 0.78) 0.003
Model 6 (95% CI) 1.00 (reference) 0.54 (0.31, 0.94) 0.41 (0.24, 0.72) 0.001
Model 7 (95% CI) 1.00 (reference) 0.57 (0.33, 0.98) 0.42 (0.24, 0.73) 0.002
Model 8 (95% CI) 1.00 (reference) 0.92 (0.40, 2.11) 0.51 (0.21, 1.24) 0.134
Female
N for knee* 4198 3159 3494 -
Knee chondrocalcinosis (%) 1.2 0.9 0.8 -
Model 1 (95% CI) 1.00 (reference) 0.64 (0.36, 1.13) 0.54 (0.30, 0.96) 0.034
Model 2 (95% CI) 1.00 (reference) 0.65 (0.36, 1.19) 0.60 (0.33, 1.09) 0.094
Model 3 (95% CI) 1.00 (reference) 0.78 (0.29, 2.13) 0.41 (0.14, 1.21) 0.091
Model 4 (95% CI) 1.00 (reference) 0.65 (0.37, 1.15) 0.54 (0.31, 0.96) 0.035
Model 5 (95% CI) 1.00 (reference) 0.65 (0.36, 1.18) 0.59 (0.33, 1.07) 0.081
Model 6 (95% CI) 1.00 (reference) 0.65 (0.35, 1.19) 0.60 (0.33, 1.10) 0.096
Model 7 (95% CI) 1.00 (reference) 0.65 (0.36, 1.14) 0.54 (0.30, 0.96) 0.034
Model 8 (95% CI) 1.00 (reference) 0.67 (0.24, 1.88) 0.37 (0.13, 1.12) 0.073
Model 1 included age (40–49, 50–59, 60–69, ≥70 years), body mass index (BMI) (<25, ≥25 kg/m2) and sex (age and BMI for the sex subgroup) (n = 12,631)
Model 2 added serum iron (tertiles) on the basis of model 1 (n = 12,149)
Model 3 added serum ferritin (tertiles) on the basis of model 1 (n = 5113)
Model 4 added serum calcium (tertiles) on the basis of model 1 (n = 12,479)
Model 5 added serum zinc (tertiles) on the basis of model 1 (n = 12,154)
Model 6 added serum copper (tertiles) on the basis of model 1 (n = 12,153)
Model 7 added serum phosphorus (tertiles) on the basis of model 1 (n = 12490)
Model 8 added education (high school or above, lower than high school) and occupation (manual labor, non-manual labor) on the basis of model 1 (n = 5844)
*Five right knees and four left knees with Kellgren-Lawrence grade 4were excluded from analysis (data from the contralateral knees were retained)
Mg magnesium, N number, CI confidence interval
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women, the average age was 52.3 ± 8.0 years, and the
mean BMI was 24.5 kg/m2 (SD = 3.3 kg/m2). The preva-
lence of knee chondrocalcinosis was 1.3% in men and
1.5% in women (Table 1).
As shown in Fig. 1, serum magnesium, even within the
normal range, was inversely associated with the OR for
knee chondrocalcinosis in a dose-response-relationship
manner (test for trend P = 0.03 for total population; P =
0.16 for the male population; P = 0.05 for the female
population). The prevalence of knee chondrocalcinosis
(knee-specific analysis) decreased from 1.3% in the low-
est tertile of serum magnesium to 0.8% in the second,
and 0.6% in the highest tertile of serum magnesium.
Figure 2 showed the linear association between the
serum magnesium and predicted prevalence of chon-
drocalcinosis. After adjusting for age, sex and BMI,
the ORs for knee chondrocalcinosis were 0.59 (95%
CI 0.40–0.87) in the middle and 0.49 (95% CI 0.33–
0.72) in the highest tertile of serum magnesium,
respectively, compared with the lowest tertile (P value
for trend <0.001). Adding each of the potential
confounders (e.g., serum iron, ferritin, calcium, zinc, cop-
per and phosphorus) into the age, sex and BMI-adjusted
model, or sensitivity analysis with exclusion of participants
with chronic renal failure, also did not change the results
materially. The association was also consistent in men and
women (Table 2). When 0.70 mmol/L was used as an add-
itional knot for spline regression, and the category ≤0.70
was used as reference group for GEE analysis, the results
did not change significantly (see Additional file 2).
XO Study I
Of 1469 participants in the XO Study I, 1316 were
included in the current analysis. About half (51.2%, n
= 674) were women, average age was 62.9 ± 8.7 years
and mean BMI was 24.2 kg/m2 (SD = 3.6). The preva-
lence of knee chondrocalcinosis was 3.1% in men and
5.0% in women (Table 3).
Serum magnesium, even within the normal range, was
inversely associated with the OR for prevalence of knee
chondrocalcinosis in a dose-response-relationship man-
ner (Fig. 3, test for trend P = 0.06 for the total popula-
tion; P = 0.25 for the male population; P = 0.14 for the
female population). As shown in Table 4, the prevalence
of knee chondrocalcinosis (knee-specific analysis) de-
creased from 4.8% in the lowest tertile of serum magne-
sium to 3.2% in the second, and 2.0% in the highest
tertile of serum magnesium. Figure 4 shows the linear
association between the serum magnesium and pre-
dicted prevalence of chondrocalcinosis. After adjusting
for age, sex and BMI, compared with the lowest tertile,
ORs for knee chondrocalcinosis were 0.67 (95% CI
0.34–1.30) in the middle and 0.45 (95% CI 0.21–0.94) in
the highest tertile of serum magnesium, respectively (P
value for trend = 0.030). Adding each of the potential
confounders (e.g., knee injury, serum parathyroid hor-
mone, iron, total iron binding capacity, unsaturated iron
binding capacity, calcium, 25(OH)D, zinc, copper and
phosphorus) into the age, sex and BMI-adjusted model,
or sensitivity analysis with exclusion of participants with
chronic renal failure or who used diuretics, also did not
change the results materially. The association was con-
sistent in men and women (Table 4). When 0.70 mmol/
L was used as an additional knot for spline regression,
and the category ≤0.70 was used as the reference group
for GEE analysis, the results did no change significantly
(see Additional file 2).
Discussion
In two population-based cross-sectional studies, we
found that serum magnesium, even within the normal
range, was inversely associated with the prevalence of
knee chondrocalcinosis in a dose-response-relationship
manner. In both studies, prevalence of knee chondrocal-
cinosis among subjects in the highest tertile of serum
Table 3 Basic characteristics of the study population in XO
Study I (n = 1316)
Tertiles of serum Mg (mmol/L)
1 (≤0.89) 2 (0.90-0.95) 3 (≥0.96)
Number 490 400 426
Median Mg level (mmol/L) 0.85 0.92 1.00
Sex (female, %) 48.6 50.3 55.2
Age (years) 63.6 ± 8.9 63.3 ± 8.4 61.6 ± 8.5
50–59 (%) 37.1 36.3 46.4
60–69 (%) 36.3 40.0 34.9
≥70 (%) 26.7 23.8 18.7
BMI (kg/m2) 24.1 ± 3.5 24.3 ± 3.9 24.3 ± 3.4
< 25 (%) 67.6 61.0 59.9
≥25 (%) 32.4 39.0 40.1
Knee injury (yes, %) 5.5 3.8 5.2
Serum PTH (μmol/L) 52.5 ± 38.0 54.8 ± 23.1 51.3 ± 20.2
Serum iron (μmol/L) 20.2 ± 8.6 19.8 ± 7.2 20.3 ± 7.8
Serum TIBC (μmol/L) 58.3 ± 11.3 59.1 ± 11.6 60.2 ± 11.4
Serum UIBC (μmol/L) 38.2 ± 13.5 39.5 ± 13.2 40.0 ± 13.1
Serum calcium (mmol/L) 2.3 ± 0.1 2.3 ± 0.1 2.3 ± 0.1
Serum 25(OH)D (μg/L) 25.8 ± 11.3 24.9 ± 9.9 25.9 ± 10.9
Serum zinc (μmol/L) 17.3 ± 3.5 18.5 ± 3.7 19.9 ± 6.1
Serum copper (μmol/L) 16.3 ± 3.2 16.4 ± 3.7 16.8 ± 3.5
Serum phosphorus (mmol/L) 1.2 ± 0.2 1.2 ± 0.2 1.2 ± 0.2
Education (educated, %) 70.2 66.5 67.8
Occupation (farmer, %) 85.5 87.3 85.7
Mg magnesium, BMI body mass index, PTH parathyroid hormone, TIBC, total
iron binding capacity, UIBC unsaturated iron-binding capacity
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magnesium was approximately 50% lower than those in
the lowest tertile of serum magnesium. Such an associ-
ation was consistent in men and women.
A few case-reports and case-series studies have shown
that chondrocalcinosis often co-occurs with hypomag-
nesemia or with hypomagnesemia owing to bowel syn-
drome and Gitelmen syndrome [7–11]. For example, in
2007 Richette et al. compared serum magnesium and
the prevalence of chondrocalcinosis in 72 patients with
intestinal failure and 72 age-matched and sex-matched
patients with back pain [6]. They found that serum mag-
nesium was significantly lower (P < 0.001) among pa-
tients with intestinal failure (0.75 mmol/L) than those
with back pain (0.81 mmol/L). On the other hand, the
prevalence of chondrocalcinosis was sevenfold higher (P
= 0.006) among patients with intestinal failure (16.6%)
than among patients with back pain (2.7%). Further-
more, serum magnesium, globular magnesium and 24-
hour urinary magnesium were significantly lower in
patients with intestinal failure than those with back pain.
Several in vivo studies have demonstrated that decreas-
ing magnesium intake induces calcification formation in
different animal models [21–24]. However, few in vivo
studies, if any, have examined the effect of magnesium
supplementation or intake on the inhibition of cartilage
calcification. In a double-blind randomized clinical trial
assessing the effect of a magnesium carbonate supplement
among patients with chronic pyrophosphate arthropathy,
there was no significant difference in the radiographic
appearance of chondrocalcinosis between the treatment
and placebo groups; however, the treatment group had a
uniform trend towards improvement in pain, stiffness, ef-
fusion, tenderness and overall subjective and objective as-
sessment compared with the placebo group over a 6-
month period [25]. This finding could be explained by the
physiologic N-methyl-D-aspartate (NMDA) receptor an-
tagonist property of magnesium, and consequently, in-
creasing serum magnesium level may reduce the
incidence of symptomatic calcium-deposition-related dis-
eases [26]. Furthermore, in a large population-based study,
Zhang et al. reported that the prevalence of knee chondro-
calcinosis was much lower among participants in the
Beijing Osteoarthritis Study than in their counterparts in
the Framingham Study (age-standardized prevalence ra-
tios = 0.34 in men and 0.43 in women); however, no differ-
ence in the levels of magnesium in the tap drinking water
was found between the two cities [5].
Several mechanisms linking magnesium and chondrocal-
cinosis have been postulated [27]. These include that high
serum magnesium may inhibit the formation of calcium
phosphate apatite and of calcium-acidic phospholipid-
phosphate complexes [28, 29], may increase the expression
of calcification inhibitors (e.g., matrix gla protein, osteopon-
tin, and bone morphogenetic protein 7), may decrease the
Fig. 3 Dose-response relationship between serum magnesium (Mg) and the odds ratio (OR) for knee chondrocalcinosis (CC) in the XO Study I. CI,
confidence interval
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Table 4 Association between serum Mg and knee chondrocalcinosis of study population in the XO Study I (n = 1316)
Tertiles of serum Mg (mmol/L) P for
trend1 (≤0.89) 2 (0.90–0.95) 3 (≥0.96)
Total
N for knee* 977 793 848 -
Knee chondrocalcinosis (%) 4.8 3.2 2.0 -
Model 1 (95% CI) 1.00 (reference) 0.67 (0.34, 1.30) 0.45 (0.21, 0.94) 0.030
Model 2 (95% CI) 1.00 (reference) 0.68 (0.35, 1.32) 0.45 (0.22, 0.94) 0.046
Model 3 (95% CI) 1.00 (reference) 0.73 (0.37, 1.47) 0.41 (0.18, 0.93) 0.028
Model 4 (95% CI) 1.00 (reference) 0.71 (0.35, 1.41) 0.41 (0.18, 0.91) 0.025
Model 5 (95% CI) 1.00 (reference) 0.73 (0.37, 1.46) 0.42 (0.19, 0.94) 0.032
Model 6 (95% CI) 1.00 (reference) 0.71 (0.36, 1.41) 0.40 (0.18, 0.91) 0.024
Model 7 (95% CI) 1.00 (reference) 0.67 (0.34, 1.30) 0.45 (0.21, 0.94) 0.030
Model 8 (95% CI) 1.00 (reference) 0.69 (0.35, 1.34) 0.45 (0.21, 0.95) 0.032
Model 9 (95% CI) 1.00 (reference) 0.71 (0.36, 1.42) 0.43 (0.20, 0.95) 0.020
Model 10 (95% CI) 1.00 (reference) 0.68 (0.35, 1.33) 0.41 (0.19, 0.88) 0.034
Model 11 (95% CI) 1.00 (reference) 0.68 (0.35, 1.32) 0.45 (0.21, 0.95) 0.033
Model 12 (95% CI) 1.00 (reference) 0.65 (0.33, 1.28) 0.46 (0.21, 0.96) 0.036
Male
N for knee* 502 397 380 -
Knee chondrocalcinosis (%) 3.8 2.5 1.1 -
Model 1 (95% CI) 1.00 (reference) 0.72 (0.26, 2.01) 0.34 (0.08, 1.37) 0.115
Model 2 (95% CI) 1.00 (reference) 0.75 (0.28, 2.05) 0.34 (0.08, 1.38) 0.114
Model 3 (95% CI) 1.00 (reference) 0.81 (0.29, 2.30) 0.39 (0.09, 1.66) 0.195
Model 4 (95% CI) 1.00 (reference) 0.78 (0.28, 2.21) 0.39 (0.09, 1.62) 0.184
Model 5 (95% CI) 1.00 (reference) 0.87 (0.31, 2.48) 0.40 (0.10, 1.64) 0.198
Model 6 (95% CI) 1.00 (reference) 0.84 (0.30, 2.35) 0.39 (0.09, 1.60) 0.183
Model 7 (95% CI) 1.00 (reference) 0.72 (0.26, 2.00) 0.34 (0.09, 1.37) 0.117
Model 8 (95% CI) 1.00 (reference) 0.65 (0.19, 2.25) 0.47 (0.11, 1.88) 0.254
Model 9 (95% CI) 1.00 (reference) 0.81 (0.27, 2.42) 0.21 (0.04, 1.08) 0.077
Model 10 (95% CI) 1.00 (reference) 0.72 (0.26, 2.00) 0.17 (0.04, 0.83) 0.024
Model 11 (95% CI) 1.00 (reference) 0.63 (0.23, 1.74) 0.32 (0.08, 1.32) 0.094
Model 12 (95% CI) 1.00 (reference) 0.67 (0.24, 1.93) 0.34 (0.08, 1.38) 0.116
Female
N for knee* 475 396 468 -
Knee chondrocalcinosis (%) 5.9 3.8 2.8 -
Model 1 (95% CI) 1.00 (reference) 0.64 (0.27, 1.52) 0.50 (0.20, 1.23) 0.128
Model 2 (95% CI) 1.00 (reference) 0.65 (0.27, 1.55) 0.50 (0.20, 1.24) 0.130
Model 3 (95% CI) 1.00 (reference) 0.66 (0.27, 1.65) 0.40 (0.15, 1.10) 0.069
Model 4 (95% CI) 1.00 (reference) 0.62 (0.25, 1.54) 0.40 (0.14, 1.09) 0.067
Model 5 (95% CI) 1.00 (reference) 0.66 (0.26, 1.63) 0.42 (0.15, 1.17) 0.090
Model 6 (95% CI) 1.00 (reference) 0.63 (0.25, 1.58) 0.41 (0.15, 1.10) 0.071
Model 7 (95% CI) 1.00 (reference) 0.64 (0.27, 1.53) 0.50 (0.20, 1.23) 0.126
Model 8 (95% CI) 1.00 (reference) 0.66 (0.27, 1.59) 0.50 (0.20, 1.23) 0.129
Model 9 (95% CI) 1.00 (reference) 0.66 (0.27, 1.59) 0.53 (0.21, 1.33) 0.174
Model 10 (95% CI) 1.00 (reference) 0.66 (0.27, 1.60) 0.53 (0.21, 1.32) 0.171
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expression of calcification promoters (e.g., alkaline
phosphatase, bone morphogenetic protein 2 and runt-
related transcription factor 2) and apoptosis [30–33],
may activate calcium-sensing receptors [34–36], modu-
late vitamin D receptor, fibroblast growth factor-1 re-
ceptor and its co-receptor klotho [36], or may block
various calcium channels to impair excessive calcium
uptake [37, 38].
Several characteristics of our study are noteworthy.
First, compared with other studies, the sample size of the
current two studies was relatively large, and the preva-
lence of knee chondrocalcinosis found in these two studies
(1.4% in the Xiangya Hospital Health Management Center
Study and 4.1% in the XO Study I) was similar to another
population-based study (i.e., the Beijing Osteoarthritis
Study) conducted among residents in Beijing (1.8% in
men and 2.7% in women) [5]. These findings suggest that
the prevalence of knee chondracalcinosis is lower than in
the predominantly white participants in the Framingham
Study [5]. In addition, we also showed that prevalence of
hypomagnesemia appeared to be lower among the partici-
pants in the current two studies than that among subjects
in the Rotterdam Study [39]. Second, an inverse associ-
ation between serum magnesium levels and prevalence of
knee chondrocalcinosis was found in our two study popu-
lations and across the sex categories, and the magnitude
of association was also quite similar when several potential
confounders (e.g., knee injury, serum parathyroid hor-
mone, iron, ferritin, total iron binding capacity, unsatur-
ated iron binding capacity, calcium, copper, zinc,
phosphorus and 25(OH)D) was added into the age, sex
and BMI adjusted model, respectively, indicating the ro-
bustness of our findings. Third, we also showed that even
within the normal range of serum magnesium, the levels
of magnesium were still inversely associated with the
prevalence of knee chondrocalcinosis in a dose-response-
relationship manner. This finding suggests that increased
serum magnesium not only among subjects with hypo-
magnesium but also among subjects who were within the
normal range of magnesium may help to reduce the risk
of chondrocalcinosis.
The prevalence of radiographic chondrocalcinosis in
the XO Study I was two to three times higher than that
in the Xiangya Hospital Health Management Center
Study. Such a difference may be due to the age differ-
ence between the two study populations in that the aver-
age age in the XO Study I (62.9 ± 8.7 years) was almost
10 years older than that in the Xiangya Hospital Health
Management Center Study (52.3 ± 8.0 years). While the
age distribution is similar in the XO Study I, and the
Beijing Osteoarthritis Study restricted participants to
60 years and older, the prevalence in the XO Study I was
higher than in the Beijing Osteoarthritis study. This may
because of the heavy physical labor (82.4% of men and
91.6% of women were farmers) and frequent climbing
(mountain area) of participants in the XO Study I, which
of course warrants further study for confirmation.
Our study has some limitations. First, this is a cross-
sectional study, thus, we cannot be certain that the
causal relationship between serum levels of magnesium
and prevalence of knee chondrocalcinosis. Second, we
did not assess the dietary intake of magnesium in rela-
tion to the prevalence of knee chondrocalcinosis in the
present study. While previous studies have shown that
dietary intake of magnesium is strongly associated with
the serum levels of magnesium [40, 41], studies of diet-
ary intake of magnesium and risk of knee chondrocalci-
nosis are warranted. Third, we did not use other views
of the knee (e.g., lateral or skyline) to ascertain radio-
graphic choncrocalcinosis; thus, it may have resulted in
underestimation of the prevalence of radiographic
CPPD. However, we postulate that such misclassification
of the prevalence of knee CPPD is likely to be non-
differential; thus the association between serum
Table 4 Association between serum Mg and knee chondrocalcinosis of study population in the XO Study I (n = 1316) (Continued)
Tertiles of serum Mg (mmol/L) P for
trend1 (≤0.89) 2 (0.90–0.95) 3 (≥0.96)
Model 11 (95% CI) 1.00 (reference) 0.68 (0.29, 1.64) 0.52 (0.21, 1.28) 0.149
Model 12 (95% CI) 1.00 (reference) 0.63 (0.26, 1.50) 0.48 (0.19, 1.21) 0.116
Model 1 included age (50–59, 60–69, ≥70 years), body mass index (BMI) (<25, ≥25 kg/m2) and sex (age and BMI for the sex subgroup) (n = 1316)
Model 2 added knee injury on the basis of model 1 (n = 1316)
Model 3 added serum parathyroid hormone (tertiles) on the basis of model 1 (n = 1250)
Model 4 added serum iron (tertiles) on the basis of model 1 (n = 1250)
Model 5 added serum total iron binding capacity (tertiles) on the basis of model 1 (n = 1241)
Model 6 added serum unsaturated iron binding capacity (tertiles) on the basis of model 1 (n = 1241)
Model 7 added serum calcium (tertiles) on the basis of model 1 (n = 1316)
Model 8 added serum 25(OH)D (tertiles) on the basis of model 1 (n = 1306)
Model 9 added serum zinc (tertiles) on the basis of model 1 (n = 1292)
Model 10 added serum copper (tertiles) on the basis of model 1 (n = 1292)
Model 11 added serum phosphorus (tertiles) on the basis of model 1 (n = 1316)
Model 12 added education (educated, non-educated) and occupation (farmer, non-farmer) on the basis of model 1 (n = 1316)
*Six right knees and eight left knees with Kellgren-Lawrence grade 4 were excluded from analysis (data from the contralateral knees were retained)
Mg magnesium, CI confidence interval
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magnesium levels and prevalence of knee radiographic
CPPD may be even stronger than we have observed. In
addition, as almost half of cases of wrist, hip, symphysis
pubis, and metacarpophalangeal joint chondrocalcinosis
occur without knee chondrocalcinosis [42], the examination
of the association of magnesium levels with a predisposition
to form CPPD crystals would ideally include radiographs
from other joint sites. Fourth, a synovial fluid test taken
from the joint should be more sensitive and specific to de-
tect crystals than radiographs, and some of the articular
CPPD deposition (alone or mixed with BCP [2, 3]) may be
too small to be detected on radiographs; thus, our estimate
of the prevalence of knee chondrocalcinosis is likely to be
underestimated. However, as we stated previously, that
prevalence estimate of knee chondrocalcinosis was similar
to another study [5] conducted in Chinese subjects that used
the same protocol to assess the presence of knee chondro-
calcinosis. The proportion of persons with chondrocalcinosis
identified on radiographs who develop clinical symptoms re-
lated to this is small. Fifth, data on some other potential
confounders (e.g., osteoporosis and use of bisphosphonates)
were not collected in either study and could impact the re-
sults. We performed sensitivity analysis to assess to what ex-
tent the residual confounding could explain the association,
using the E-value proposed by VanderWeele and Ding [43].
The observed OR of 0.49 for prevalence with the highest
levels of magnesium in Xiangya Hospital Health Manage-
ment Center Study could be explained if an OR of an un-
measured confounder with either high serum magnesium or
with the prevalence of chondrocalcinosis is at least 3.50,
which is above and beyond the measured confounders.
There should be a similar magnitude of residual con-
founders to explain the findings in the XO Study I. To our
best knowledge we are unaware that there is such a strong
confounder between magnesium and the prevalence of
chondrocalcinosis.
Our study findings have potential clinical implications.
The existing in vivo and in vitro studies showed that
magnesium supplementation may have a protective ef-
fect on cartilage or chondrocytes [44]. Two large epi-
demiological studies conducted in twins and in the
general population reported an inverse association be-
tween serum magnesium levels and radiographic knee
osteoarthritis [12, 45]. Furthermore, several studies have
reported that chondrocalcinosis may be a potential risk
factor for osteoarthritis [46–52]. Thus, it is not unrea-
sonable to speculate that increasing serum magnesium
may be beneficial in decreasing the risk of osteoarthritis
through reducing the incidence of chondrocalcinosis.
Future studies are warranted to test this hypothesis.
Conclusions
We found that low serum magnesium, even within the
normal range, was associated with higher prevalence of
knee chondrocalcinosis in a dose-response-relationship
manner. Future studies of dietary intake, including mag-
nesium supplementary intake, on the risk of chondrocal-
cinosis are warranted.
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